Skip to content

Diagnostics and Surveillance of Acute Meningo-encephalitis Among Children in Cambodia With a Focus on Japanese Encephalitis Virus

Diagnostics and Surveillance of Acute Meningo-encephalitis Among Children in Cambodia With a Focus on Japanese Encephalitis Virus

Status
Not yet recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06674837
Acronym
DEMELE-JEV
Enrollment
4000
Registered
2024-11-05
Start date
2025-10-15
Completion date
2028-01-31
Last updated
2025-09-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Japanese Encephalitis

Keywords

Japanese encephalitis, arbovirus

Brief summary

The primary objective of this study is to quantify the clinical burden of Japanese Encephalitis (JE) and the asymptomatic circulation of JEV among Cambodian children, through two pediatric cohorts: non-febrile children at recruitment and children hospitalized with febrile neurological syndrome (FNS). Secondary objectives include estimating anti-JEV seropositivity rates, identifying individual risk factors and living conditions associated with JEV infection, characterizing clinical and biological profiles related to disease severity, and evaluating the role of deficiencies in interferon (IFN) response in severe JEV infections.

Detailed description

This is an observational prospective study (with cross-sectional and longitudinal designs) involving two pediatric cohorts recruited from Kantha Bopha hospitals in Phnom Penh and Siem Reap. Group 1 will consist of 2000 non-febrile children aged 2-14 years, recruited from trauma units and followed up for two years to monitor JEV seroconversion. Group 2 will include 2000 children hospitalized with FNS, confirmed JE participants will be followed up for one year to assess the severity of JEV infection. Diagnostic tools such as the QIAstat molecular diagnostic platform and ELISA will be used to detect multiple pathogens, including JEV and dengue virus (DENV). Data collection will involve clinical assessments, etiological testing, and environmental surveys. All collected information will be integrated into a centralized database for analysis.

Interventions

None listed

Sponsors

ANRS, Emerging Infectious Diseases
Lead SponsorOTHER_GOV

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
2 Years to 14 Years
Healthy volunteers
Yes

Inclusion criteria

Cohort 1 * All children aged between 2 and 14 years. * No fever or history of fever in the past 14 days. * Consenting to return to the hospital for follow-up visits. * Consenting to blood sampling. * Written informed assent/consent to participate in the study. Cohort 2 * Hospitalized patients aged between 2 and 14 years. * Any neurological disorder. * Any fever within the past 72 hours. * Written informed assent/consent to participate in the study. * No contraindication for lumbar puncture (LP).

Design outcomes

Primary

MeasureTime frameDescription
To quantify Japanese Encephalitis Virus seroconversion in a cohort of asymptomatic children aged 2-14 years24 monthsJapanese Encephalitis Virus seroconversion will be determined based on PCR positivity or ELISA results, with confirmatory testing by virus neutralization assays. Unit of Measure: Binary measure (presence or absence) of JEV antibodies or presence of JEV RNA

Secondary

MeasureTime frameDescription
To assess factors related to the clinical severity of JEV infection among children hospitalized with febrile neurological symptoms (FNS) who are confirmed JEV cases.12 monthsSeverity will be evaluated based on the following clinical indicators: * Length of hospital stay (measured in days). * Presence of neurological sequelae (binary outcome: presence or absence). * Mortality (binary outcome: survival or death). Unit of Measure: Days for hospitalization length; binary measures for sequelae and mortality.

Contacts

Primary ContactDiana Molino, PhD
diana.molino@inserm.fr+33 1 53 94 60 76

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026